首款“口服版减肥神药”获批 诺和诺德(NVO.US)盘前涨超8%

Core Viewpoint - Novo Nordisk's stock surged over 8% to $52.29 following the FDA's approval of its first oral GLP-1 weight loss drug, Wegovy, which will launch in the U.S. in early January at a starting cash price of $149 per month [1] Group 1: Product Approval and Market Position - The FDA has approved Novo Nordisk's oral version of Wegovy, providing the company with a competitive edge over Eli Lilly [1] - Wegovy's clinical data indicates it can help patients lose up to 16.6% of their body weight and reduce cardiovascular risks [1] - Eli Lilly's own oral weight loss drug is expected to receive approval in March next year, giving Novo Nordisk a few months of valuable market window to solidify its first-mover advantage [1]